NASDAQ
15.90USD
0.00 (-4.96%)
We have scored 3 news catalysts on SWK Holdings Corporation (SWKH) over the past 12 months. The biggest single-day move next to one of them came Oct 9, 2025, when SWKH closed −0.3%: “Runway Growth Finance Corp. to Acquire SWK Holdings Corporation”. Coverage across the window leans mixed (average ticker sentiment +0.03). Most of the impact sits in institutional appeal and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
192.3M
P/E
—
EPS
—
Beta
0.30
52W range
12.54358-17.9
Day range
15.90–15.90
Open
15.90
Prev close
15.90
Volume
105.6K
Avg volume
9.4K
Dividend
4.00
IPO
1999-09-23
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about SWK Holdings Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of SWK Holdings Corporation, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for SWKH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
SWK Holdings Corporation (SWKH) operates as a specialized financial institution, primarily concentrating its efforts within the healthcare sector. The company's operations are distinctly divided into two core segments: Finance Receivables and Pharmaceutical Development. Within its finance division, SWK offers bespoke funding solutions tailored to a diverse array of life science enterprises. These include companies spanning biotechnology, medical devices, diagnostic tools, animal health, and pharmaceuticals, alongside various institutions and individual innovators. Furthermore, the company extends non-discretionary investment advisory services, managing separate accounts for institutional clients keen on investing in the life science finance domain. Its Pharmaceutical Development segment involves the creation, formulation, production, and licensing of pharmaceutical products, leveraging its proprietary Peptelligence platform. A key strategic objective here is to license its internally developed product pipeline to external partners, aiming to generate innovative formulations through its unique technology, ultimately designed to benefit patients and their caregivers. Founded in 1996, the company underwent a name change from Kana Software, Inc. to SWK Holdings Corporation in December 2009. Its corporate headquarters are situated in Dallas, Texas.
